Cyclerion Therapeutics Stock Forecast, Price & News

Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

Is Cyclerion Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cyclerion Therapeutics stock.
View analyst ratings for Cyclerion Therapeutics or view top-rated stocks.

How has Cyclerion Therapeutics' stock price been impacted by COVID-19?

Cyclerion Therapeutics' stock was trading at $2.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CYCN stock has decreased by 39.0% and is now trading at $1.77.
View which stocks have been most impacted by COVID-19.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a increase in short interest in October. As of October 29th, there was short interest totaling 1,450,000 shares, an increase of 17.9% from the October 14th total of 1,230,000 shares. Based on an average trading volume of 363,900 shares, the days-to-cover ratio is currently 4.0 days.
View Cyclerion Therapeutics' Short Interest.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cyclerion Therapeutics.

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) issued its earnings results on Tuesday, November, 9th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.09. Cyclerion Therapeutics had a negative trailing twelve-month return on equity of 104.73% and a negative net margin of 1,696.27%.
View Cyclerion Therapeutics' earnings history.

What price target have analysts set for CYCN?

3 analysts have issued twelve-month price targets for Cyclerion Therapeutics' shares. Their forecasts range from $7.00 to $14.00. On average, they anticipate Cyclerion Therapeutics' share price to reach $11.67 in the next twelve months. This suggests a possible upside of 559.1% from the stock's current price.
View analysts' price targets for Cyclerion Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Cyclerion Therapeutics' key executives?

Cyclerion Therapeutics' management team includes the following people:

• Peter M. Hecht, CEO, CFO, Director & Chief Accounting Officer (LinkedIn Profile)
• Cheryl Gault, Chief Operating Officer
• Andreas Eugen Busch, Chief Scientific Officer
• Kevin Durfee, Vice President-Information Technology & Facilities
• G. Todd Milne, Vice President-Corporate Development

Who are some of Cyclerion Therapeutics' key competitors?

Some companies that are related to Cyclerion Therapeutics include KalVista Pharmaceuticals (KALV), Evolus (EOLS), Relmada Therapeutics (RLMD), Aeglea BioTherapeutics (AGLE), Nanobiotix (NBTX), Theratechnologies (THTX), Biomea Fusion (BMEA), MEI Pharma (MEIP), Eliem Therapeutics (ELYM), Applied Therapeutics (APLT), Homology Medicines (FIXX), Kamada (KMDA), KemPharm (KMPH), Akouos (AKUS) and Verona Pharma (VRNA).
View all of CYCN's competitors.

What other stocks do shareholders of Cyclerion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclerion Therapeutics investors own include Fulcrum Therapeutics (FULC), Ovid Therapeutics (OVID), Spectrum Pharmaceuticals (SPPI), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Pharmaceuticals (XERS), Abeona Therapeutics (ABEO), ACADIA Pharmaceuticals (ACAD), Aimmune Therapeutics (AIMT) and Celldex Therapeutics (CLDX).

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

Who are Cyclerion Therapeutics' major shareholders?

Cyclerion Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Two Sigma Advisers LP (1.50%), Geode Capital Management LLC (1.13%), Pura Vida Investments LLC (0.97%), Two Sigma Investments LP (0.90%), Eversept Partners LP (0.86%) and Millennium Management LLC (0.70%). Company insiders that own Cyclerion Therapeutics stock include Andreas Busch, Mark G Currie, Peter M Hecht, Peter M Hecht, Slate Path Capital Lp, Terrance Mcguire and William Huyett.
View institutional ownership trends for Cyclerion Therapeutics.

Which major investors are selling Cyclerion Therapeutics stock?

CYCN stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Pura Vida Investments LLC, Citadel Advisors LLC, and Dimensional Fund Advisors LP.
View insider buying and selling activity for Cyclerion Therapeutics or view top insider-selling stocks.

Which major investors are buying Cyclerion Therapeutics stock?

CYCN stock was acquired by a variety of institutional investors in the last quarter, including Eversept Partners LP, Two Sigma Advisers LP, Two Sigma Investments LP, Franklin Resources Inc., Geode Capital Management LLC, Jump Financial LLC, Jane Street Group LLC, and Goldman Sachs Group Inc.. Company insiders that have bought Cyclerion Therapeutics stock in the last two years include Andreas Busch, Peter M Hecht, Slate Path Capital Lp, and Terrance Mcguire.
View insider buying and selling activity for Cyclerion Therapeutics or or view top insider-buying stocks.

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $1.77.

How much money does Cyclerion Therapeutics make?

Cyclerion Therapeutics has a market capitalization of $76.68 million and generates $2.30 million in revenue each year.

How many employees does Cyclerion Therapeutics have?

Cyclerion Therapeutics employs 51 workers across the globe.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is www.cyclerion.com.

Where are Cyclerion Therapeutics' headquarters?

Cyclerion Therapeutics is headquartered at 301 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at (857) 327-8778 or via email at [email protected].